Ftse Mib
34.494,29
-0,95%
DAX
18.676,90
-0,48%
S&P 500
5.308,13
0,09%
NASDAQ
16.794,87
0,65%
Bitcoin
70.959,85
-0,69%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ PharmaCyte Biotech Inc (PMCB) PharmaCyte Biotech Inc (PMCB) Notizie

PMCB

PharmaCyte Biotech (PMCB)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PMCB
DataOraFonteTitoloSimboloCompagnia
14/02/202421:38Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:PMCBPharmaCyte Biotech Inc
06/02/202415:56Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:PMCBPharmaCyte Biotech Inc
15/12/202323:25Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PMCBPharmaCyte Biotech Inc
28/11/202323:06Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:PMCBPharmaCyte Biotech Inc
24/11/202322:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PMCBPharmaCyte Biotech Inc
22/11/202323:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PMCBPharmaCyte Biotech Inc
22/11/202322:00Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:PMCBPharmaCyte Biotech Inc
15/11/202314:30Business WirePharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc.NASDAQ:PMCBPharmaCyte Biotech Inc
31/10/202314:15Business WirePharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box TechnologyNASDAQ:PMCBPharmaCyte Biotech Inc
02/10/202306:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PMCBPharmaCyte Biotech Inc
21/09/202323:04Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:PMCBPharmaCyte Biotech Inc
15/09/202323:00Edgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBNASDAQ:PMCBPharmaCyte Biotech Inc
31/07/202323:18Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:PMCBPharmaCyte Biotech Inc
31/07/202322:42Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:PMCBPharmaCyte Biotech Inc
19/07/202316:28Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:PMCBPharmaCyte Biotech Inc
16/06/202323:23Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:PMCBPharmaCyte Biotech Inc
15/06/202322:02Edgar (US Regulatory)Amended Tender Offer Statement by Issuer (sc To-i/a)NASDAQ:PMCBPharmaCyte Biotech Inc
15/06/202315:15Business WirePharmaCyte Biotech Announces Final Results of Tender OfferNASDAQ:PMCBPharmaCyte Biotech Inc
05/06/202322:06Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:PMCBPharmaCyte Biotech Inc
25/05/202323:14Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:PMCBPharmaCyte Biotech Inc
19/05/202323:20Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:PMCBPharmaCyte Biotech Inc
11/05/202314:30Business WirePharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per ShareNASDAQ:PMCBPharmaCyte Biotech Inc
16/03/202321:43Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:PMCBPharmaCyte Biotech Inc
14/02/202322:52Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:PMCBPharmaCyte Biotech Inc
02/02/202315:16Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:PMCBPharmaCyte Biotech Inc
02/02/202315:00Business WirePharmaCyte Biotech to Implement Second $10-Million Share Repurchase PlanNASDAQ:PMCBPharmaCyte Biotech Inc
30/12/202222:06Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:PMCBPharmaCyte Biotech Inc
30/12/202222:06Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:PMCBPharmaCyte Biotech Inc
11/10/202210:45TipRanksH.C. Wainwright Keeps Their Hold Rating on PharmaCyte Biotech (PMCB)NASDAQ:PMCBPharmaCyte Biotech Inc
07/10/202215:00GlobeNewswire Inc.PharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder ValueNASDAQ:PMCBPharmaCyte Biotech Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PMCB

La tua Cronologia

NYSE
BLT
Blount
COIN
ARCOUSD
COIN
DO2UST
DO2 Token
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network